abstract |
The present invention is a method for improving the bioavailability of a renin inhibitor, preferably a δ-amino-γ-hydroxy-ω-aryl-alkanoic acid derivative, to mammals, especially humans, in need of such treatment. , A renin inhibitor, or a pharmaceutically acceptable salt thereof, and a combination of an efflux protein inhibitor. |